Novel Techniques and Models for Studying the Role of the Gut Microbiota in Drug Metabolism

被引:4
作者
Tan, Jianling [1 ,2 ]
Fu, Bingxuan [1 ,2 ]
Zhao, Xiaojie [1 ,2 ]
Ye, Ling [1 ,2 ]
机构
[1] Southern Med Univ, Sch Pharmaceut Sci, NMPA Key Lab Res & Evaluat Drug Metab, Guangzhou 510515, Peoples R China
[2] Southern Med Univ, Sch Pharmaceut Sci, Guangdong Prov Key Lab New Drug Screening, Guangzhou 510515, Peoples R China
基金
中国国家自然科学基金;
关键词
GRADIENT GEL-ELECTROPHORESIS; HUMAN INTESTINAL MICROBIOTA; ANTIBIOTICS; ENZYMES; IDENTIFICATION; INACTIVATION; DILTIAZEM;
D O I
10.1007/s13318-023-00874-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The gut microbiota, known as the second human genome, plays a vital role in modulating drug metabolism, significantly impacting therapeutic outcomes and adverse effects. Emerging research has elucidated that the microbiota mediates a range of modifications of drugs, leading to their activation, inactivation, or even toxication. In diverse individuals, variations in the gut microbiota can result in differences in microbe-drug interactions, underscoring the importance of personalized approaches in pharmacotherapy. However, previous studies on drug metabolism in the gut microbiota have been hampered by technical limitations. Nowadays, advances in biotechnological tools, such as microbially derived metabolism screening and microbial gene editing, have provided a deeper insight into the mechanism of drug metabolism by gut microbiota, moving us toward personalized therapeutic interventions. Given this situation, our review summarizes recent advances in the study of gut-microbiota-mediated drug metabolism and showcases techniques and models developed to navigate the challenges posed by the microbial involvement in drug action. Therefore, we not only aim at understanding the complex interaction between the gut microbiota and drugs and outline the development of research techniques and models, but we also summarize the specific applications of new techniques and models in researching gut-microbiota-mediated drug metabolism, with the expectation of providing new insights on how to study drug metabolism by gut microbiota.
引用
收藏
页码:131 / 147
页数:17
相关论文
共 103 条
  • [1] Discovery of drug-omics associations in type 2 diabetes with generative deep-learning models
    Allesoe, Rosa Lundbye
    Lundgaard, Agnete Troen
    Medina, Ricardo Hernandez
    Aguayo-Orozco, Alejandro
    Johansen, Joachim
    Nissen, Jakob Nybo
    Brorsson, Caroline
    Mazzoni, Gianluca
    Niu, Lili
    Biel, Jorge Hernansanz
    Brasas, Valentas
    Webel, Henry
    Benros, Michael Eriksen
    Pedersen, Anders Gorm
    Chmura, Piotr Jaroslaw
    Jacobsen, Ulrik Plesner
    Mari, Andrea
    Koivula, Robert
    Mahajan, Anubha
    Vinuela, Ana
    Tajes, Juan Fernandez
    Sharma, Sapna
    Haid, Mark
    Hong, Mun-Gwan
    Musholt, Petra B.
    De Masi, Federico
    Vogt, Josef
    Pedersen, Helle Krogh
    Gudmundsdottir, Valborg
    Jones, Angus
    Kennedy, Gwen
    Bell, Jimmy
    Thomas, E. Louise
    Frost, Gary
    Thomsen, Henrik
    Hansen, Elizaveta
    Hansen, Tue Haldor
    Vestergaard, Henrik
    Muilwijk, Mirthe
    Blom, Marieke T.
    Hart, Leen M. T.
    Pattou, Francois
    Raverdy, Violeta
    Brage, Soren
    Kokkola, Tarja
    Heggie, Alison
    McEvoy, Donna
    Mourby, Miranda
    Kaye, Jane
    Hattersley, Andrew
    [J]. NATURE BIOTECHNOLOGY, 2023, 41 (03) : 399 - +
  • [2] Significant pharmacokinetic differences of berberine are attributable to variations in gut microbiota between Africans and Chinese
    Alolga, Raphael N.
    Fan, Yong
    Chen, Zhuo
    Liu, Li-Wei
    Zhao, Yi-Jing
    Li, Jin
    Chen, Yan
    lai, Mao-De
    Li, Ping
    Qi, Lian-Wen
    [J]. SCIENTIFIC REPORTS, 2016, 6
  • [3] Advances in Oral Drug Delivery
    Alqahtani, Mohammed S.
    Kazi, Mohsin
    Alsenaidy, Mohammad A.
    Ahmad, Muhammad Z.
    [J]. FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [4] Scalable metagenomic taxonomy classification using a reference genome database
    Ames, Sasha K.
    Hysom, David A.
    Gardner, Shea N.
    Lloyd, G. Scott
    Gokhale, Maya B.
    Allen, Jonathan E.
    [J]. BIOINFORMATICS, 2013, 29 (18) : 2253 - 2260
  • [5] Data mining analysis of terminal restriction fragment length polymorphism shows geographical differences in the human gut microbiota
    Andoh, Akira
    Kobayashi, Toshio
    Kuzuoka, Hiroyuki
    Suzuki, Yasuo
    Matsui, Toshiyuki
    Nakamura, Shiro
    Matsumoto, Takayuki
    Fujiyama, Yoshihide
    Bamba, Tadao
    [J]. BIOMEDICAL REPORTS, 2013, 1 (04) : 559 - 562
  • [6] An Improved Method for High Quality Metagenomics DNA Extraction from Human and Environmental Samples
    Bag, Satyabrata
    Saha, Bipasa
    Mehta, Ojasvi
    Anbumani, D.
    Kumar, Naveen
    Dayal, Mayanka
    Pant, Archana
    Kumar, Pawan
    Saxena, Shruti
    Allin, Kristine H.
    Hansen, Torben
    Arumugam, Manimozhiyan
    Vestergaard, Henrik
    Pedersen, Oluf
    Pereira, Verima
    Abraham, Philip
    Tripathi, Reva
    Wadhwa, Nitya
    Bhatnagar, Shinjini
    Prakash, Visvanathan Gnana
    Radha, Venkatesan
    Anjana, R. M.
    Mohan, V.
    Takeda, Kiyoshi
    Kurakawa, Takashi
    Nair, G. Balakrish
    Das, Bhabatosh
    [J]. SCIENTIFIC REPORTS, 2016, 6
  • [7] Mass spectrometry based metabolomics and enzymatic assays for functional genomics
    Baran, Richard
    Reindl, Wolfgang
    Northen, Trent R.
    [J]. CURRENT OPINION IN MICROBIOLOGY, 2009, 12 (05) : 547 - 552
  • [8] THE PHARMACOKINETICS AND PHARMACODYNAMICS OF DILTIAZEM AND ITS METABOLITES IN HEALTHY-ADULTS AFTER A SINGLE ORAL DOSE
    BOYD, RA
    CHIN, SK
    DONPEDRO, O
    VEROTTA, D
    SHEINER, LB
    WILLIAMS, RL
    GIACOMINI, KM
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 46 (04) : 408 - 419
  • [9] [陈怀侠 CHEN Huaixia], 2007, [质谱学报, Journal of Chinese Mass Spectrometry Society], V28, P169
  • [10] The role of gut microbiota in cancer treatment: friend or foe?
    Cheng, Wing Yin
    Wu, Chun-Ying
    Yu, Jun
    [J]. GUT, 2020, 69 (10) : 1867 - 1876